BridgeBio Pharma, Inc. (BBIO) stock
BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$76.80−0.56 (-0.72%)
Close on Nov 17, 2026Market cap $14.96BP/E –Yield –
BridgeBio Pharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
BridgeBio Pharma's revenue for the twelve months ending Sep 30, 2026 was $945.54M, up 167.3% year over year. For fiscal 2025 it was $502.08M, up 126.3% from the year before. The highest annual figure on record is $502.08M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $502.08M | +126.3% |
| FY2024 | Dec 31, 2024 | $221.90M | +2285.3% |
| FY2023 | Dec 31, 2023 | $9.30M | -88.0% |
| FY2022 | Dec 31, 2022 | $77.65M | +11.4% |
| FY2021 | Dec 31, 2021 | $69.72M | +745.1% |
| FY2020 | Dec 31, 2020 | $8.25M | -79.7% |
| FY2019 | Dec 31, 2019 | $40.56M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $353.17M | +192.6% |
| Q2 FY2026 | Jun 30, 2026 | $243.68M | +120.4% |
| Q1 FY2026 | Mar 31, 2026 | $194.52M | +66.8% |
| Q4 FY2025 | Dec 31, 2025 | $154.18M | +2521.2% |
| Q3 FY2025 | Sep 30, 2025 | $120.70M | +4318.0% |
| Q2 FY2025 | Jun 30, 2025 | $110.57M | +4999.9% |
| Q1 FY2025 | Mar 31, 2025 | $116.63M | -44.8% |
| Q4 FY2024 | Dec 31, 2024 | $5.88M | +237.1% |
| Q3 FY2024 | Sep 30, 2024 | $2.73M | -33.2% |
| Q2 FY2024 | Jun 30, 2024 | $2.17M | +32.1% |
| Q1 FY2024 | Mar 31, 2024 | $211.12M | +11461.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.75M | -6.7% |
| Q3 FY2023 | Sep 30, 2023 | $4.09M | +1110.4% |
| Q2 FY2023 | Jun 30, 2023 | $1.64M | -97.8% |
| Q1 FY2023 | Mar 31, 2023 | $1.83M | +7.8% |
| Q4 FY2022 | Dec 31, 2022 | $1.87M | -85.5% |
| Q3 FY2022 | Sep 30, 2022 | $338.00K | -85.6% |
| Q2 FY2022 | Jun 30, 2022 | $73.75M | +36.5% |
| Q1 FY2022 | Mar 31, 2022 | $1.69M | +266.7% |
| Q4 FY2021 | Dec 31, 2021 | $12.89M | +10462.3% |
| Q3 FY2021 | Sep 30, 2021 | $2.34M | -71.2% |
| Q2 FY2021 | Jun 30, 2021 | $54.02M | +290.9% |
| Q1 FY2021 | Mar 31, 2021 | $462.00K | -98.3% |
| Q4 FY2020 | Dec 31, 2020 | $122.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $8.13M | – |
| Q4 FY2019 | Dec 31, 2019 | $13.82M | – |
| Q3 FY2019 | Sep 30, 2019 | $26.74M | – |
See a number that looks wrong?